OverviewChartNewsTraderScreen

UBS Knock-Out BNTX/  DE000UK14XL2  /

UBS Investment Bank
2024-06-03  5:18:33 PM Chg.+0.190 Bid5:18:33 PM Ask5:18:33 PM Underlying Strike price Expiration date Option type
1.740EUR +12.26% 1.740
Bid Size: 25,000		 1.750
Ask Size: 25,000		 BioNTech SE 84.9112 USD 2078-12-31 Call
GlobeNewswire 06-01 Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates M...
GlobeNewswire 05-29 BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
GlobeNewswire 05-28 Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology ...
GlobeNewswire 05-21 BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO A...
GlobeNewswire 05-21 Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announ...
GlobeNewswire 05-17 BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
GlobeNewswire 05-17 Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
GlobeNewswire 05-09 Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
TeleTrader 05-06 BioNTech's Q1 revenue slumps 85% to €187.6M
GlobeNewswire 05-06 BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
TeleTrader 05-06 Europe mixed premarket with data on the limelight
GlobeNewswire 05-02 Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire 04-22 BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
GlobeNewswire 04-10 Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first...
GlobeNewswire 04-07 Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persis...
GlobeNewswire 04-04 Medigene AG Secures European Patent for its iM-TCR Technology
GlobeNewswire 03-28 Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire 03-27 Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
TeleTrader 03-20 BioNTech Q4 revenue plunges 65% to €1.48B
GlobeNewswire 03-20 BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
GlobeNewswire 03-20 BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
TeleTrader 03-20 Europe mixed premarket amid data
GlobeNewswire 03-14 Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
GlobeNewswire 03-12 The Gross Law Firm Notifies BioNTech SE Investors of a Class Action Lawsuit and Upcoming Deadline – ...
GlobeNewswire 03-11 BNTX DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Co...